Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443

Mise à jour : Il y a 4 ans
Référence : NCT00631475

Femme et Homme

Extrait

This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).


Critère d'inclusion

  • Idiopathic pulmonary fibrosis


Liens